Nucletron completes management buy-out

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Nucletron announced today that a management team has bought out Delft Instruments, thus creating an independent company dedicated to radiation oncology. Since its inception in 1974, Nucletron has operated several entities in the field of radiation oncology throughout the world. Collaborative partnerships, pioneering research and development of advanced technological innovations will enable Nucletron to more effectively deliver cancer treatment solutions globally, the company said in an announcement.

The creation of an independent Nucletron is the result of the company's success in the past two years," said CEO David Imperiali. "Nucletron has a strong tradition of innovation in radiotherapy, and the breadth of our capability positions the company well to continue to make significant contributions to the treatment of cancer."

The previous company, under Delft Instruments, was created in 1994 by merging Nucletron, a provider of brachytherapy solutions, with the Oldelft Simulix brand of radiation therapy simulation and imaging technology. Additionally, in 2003, Nucletron integrated the Helax and Theratronics treatment planning and management solutions, from MDS Nordion, into its portfolio to create Oncentra MasterPlan and Oncentra Information Management.

"Nucletron's ability to restructure itself, anticipate needs, and incorporate new state-of-the-art products and services into our solutions suite gives us the ability to create strong and long-lasting relationships with our customers and partners," said COO Jeroen Cammeraat. "The new corporate structure gives us the flexibility and agility to continue to develop world-class solutions for our customers and partners, focused on improving patient care."

Nucletron dedicates more than 10 percent of its revenues in research and development. Headquartered in The Netherlands, Nucletron delivers customized solutions to more than 3,000 institutions in more than 120 countries. The company will continue to operate offices in 16 countries, including a production and R &D facility in The Netherlands, R &D centers in Uppsala, Sweden and Oslo, Norway and sales, marketing, service and support operations in Europe, Asia, Australia and North America.
The supervisory board of Nucletron will be chaired by Rob Westerhof, who has held senior positions in Asia and in the United States for Philips Medical Systems and Philips Electronics.